Table 1.
Patient Characteristics
| Total (n = 73) | Hospitalized (n = 9) | Nonhospitalized (n = 64) | P Valuea | |
|---|---|---|---|---|
| Age, median (IQR), y | 59 (49–67) | 62 (60–74) | 57 (49–67) | .16 |
| Male gender, No. (%) | 46 (63.0) | 7 (77.8) | 39 (60.9) | .47 |
| Bamlanivimab, No. (%) | 55 (75.3) | 8 (88.9) | 47 (73.4) | .44b |
| Casirivimab-imdevimab, No. (%) | 18 (24.7) | 1 (11.1) | 17 (26.6) | |
| Time from symptom onset to antibody administration, median (IQR), d | 4 (3–7) | 6 (4–7) | 4 (2–6.25) | .03 |
| Time from positive COVID-19 testing to antibody administration, median (IQR), d | 2 (1–2) | 2 (2–2) | 1 (1–2.25) | .24 |
| BMI, median (IQR), kg/m2 | 29.17 (25.78–33.01) | 31.91 (27.53–32.9) | 28.75 (25.37–33.08) | .22 |
| Kidney, No. (%) | 41 (56.2) | 7 (77.8) | 34 (53.1) | .28c |
| Kidney-pancreas, No. (%) | 4 (5.5) | 0 | 4 (6.3) | |
| Liver, No. (%) | 13 (17.8) | 0 | 13 (20.3) | |
| Heart, No. (%) | 11 (15.1) | 2 (22.2) | 9 (14.1) | |
| Heart-liver, No. (%) | 1 (1.4) | 0 | 1 (1.6) | |
| Lung, No. (%) | 2 (2.7) | 0 | 2 (3.1) | |
| Pancreas, No. (%) | 1 (1.4) | 0 | 1 (1.6) | |
| Prednisone, No. (%) | 45 (61.6) | 8 (88.9) | 37 (57.8) | .14 |
| Tacrolimus, No. (%) | 64 (87.7) | 8 (88.9) | 56 (87.5) | 1 |
| Cyclosporine, No. (%) | 2 (2.7) | 0 | 2 (3.1) | 1 |
| Sirolimus, No. (%) | 6 (8.2) | 0 | 6 (9.4) | 1 |
| Mycophenolate, No. (%) | 57 (78.1) | 7 (77.8) | 50 (78.1) | 1 |
| Azathioprine, No. (%) | 2 (2.7) | 0 | 2 (3.1) | 1 |
| Belatacept, No. (%) | 3 (4.1) | 1 (11.1) | 2 (3.1) | .33 |
| Recent rejection, No. (%) | 3 (4.1) | 0 | 3 (4.7) | 1 |
| Time from transplant, median (IQR), d | 1777 (729–3582) | 1503 (366–1829) | 1890 (801.75–3821.25) | .22 |
| CAD, No. (%) | 13 (17.8) | 3 (33.3) | 10 (15.6) | .19 |
| CHF, No. (%) | 7 (9.6) | 2 (22.2) | 5 (7.8) | .20 |
| Hypertension, No. (%) | 48 (65.8) | 9 (100) | 39 (60.9) | .023 |
| Diabetes mellitus, No. (%) | 31 (42.5) | 3 (33.3) | 28 (43.8) | .72 |
| CKD, No. (%) | 40 (54.8) | 6 (66.7) | 34 (53.1) | .50 |
| Malignancy, No. (%) | 16 (21.9) | 3 (33.3) | 13 (20.3) | .40 |
| Chronic lung disease, No. (%) | 8 (11.0) | 1 (11.1) | 7 (10.9) | 1 |
| Chronic liver disease, No. (%) | 9 (12.3) | 0 | 9 (14.1) | .59 |
| Current tobacco use, No. (%) | 2 (2.7) | 0 | 2 (3.1) | 1 |
| Previous tobacco use, No. (%) | 26 (35.6) | 4 (44.4) | 22 (34.4) | .71 |
| CCI, median (IQR) | 5 (3–7) | 6 (4–8) | 5 (3–7) | .30 |
Bold indicates P value that reach statistical significance.
Abbreviations: BMI, body mass index; CAD, coronary artery disease; CCI, Charlson comorbidity index; CHF, congestive heart failure; CKD, chronic kidney disease; IQR, interquartile range.
aComparison of hospitalized and nonhospitalized groups.
bComparing risk of hospitalization for bamlanivimab and casirivimab-imdevimab.
cComparing risk of hospitalization for kidney transplant and non–kidney transplant.